SLC10A3 drives glioblastoma progression by remodeling the immunosuppressive microenvironment and promoting M2 macrophage migration - Top-Institutions - MDSpire

SLC10A3 drives glioblastoma progression by remodeling the immunosuppressive microenvironment and promoting M2 macrophage migration

  • By

  • Shuhui Chen

  • Daogang Qin

  • Hanyang Lin

  • Taohui Ding

  • Wei Liu

  • Ziqi Yan

  • Lingting Wang

  • Bo Kou

  • May 13, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Neurosurgery
    • Radiation Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Neurosurgery
    • Radiation Oncology

  • #3

    University of Pittsburgh
    University of Pittsburgh

    Pittsburgh, Pennsylvania

    Key Differentiators

    • Oncology
    • Neurosurgery

  • #4

    Shanghai Pulmonary Hospital
    Shanghai Pulmonary Hospital

    Shanghai, China

    Key Differentiators

    • Oncology
    • Pulmonology

  • #5

    Tongji University School of Medicine
    Tongji University School of Medicine

    Shanghai, China

    Key Differentiators

    • Oncology
    • Medical Research

Original Source(s)

SLC10A3 drives glioblastoma progression by remodeling the immunosuppressive microenvironment and promoting M2 macrophage migration

  • by Shuhui Chen, Daogang Qin, Hanyang Lin, Taohui Ding, Wei Liu, Ziqi Yan, Lingting Wang, Bo Kou

  • May 13, 2026

Related Content

Ultraviolet radiation as a double-edged regulator of melanocyte function in vitiligo therapy and melanoma carcinogenesis

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia